Feb 3, 2022
Author: Matt Halpert
As we launch into a new year, The Clayco Foundation is set to expand and accelerate efforts within the realm of Retinal Vasculopathy with Cerebral Leukoencephalopathy (RVCL), a rare genetic disorder that needs more attention. This will include a focus on education, aiding in earlier patient identification, promoting research, and propelling treatment options into the clinic.
Education and Patient Identification will be critical to all efforts to expand research, trials, and treatment options. Because RVCL is rare, and early RVCL symptoms can mimic symptoms of other more frequent diseases, an RVCL diagnosis is often delayed. Though an understandable outcome, this can be detrimental to the patient, stressful to the doctors, and a failure to promote relevant research and treatments. As part of RVCL.org, we will strive to increase awareness within the appropriate medical communities about when an RVCL diagnosis may be appropriate and how to test for it…
…. the Clayco Foundation will cover the costs of such tests for all appropriate patients.
Research is the life-blood of advancements in treatment options for all diseases, and RVCL is no different. As part of this initiative, the Clayco Foundation is providing funding for motivated scientists and doctors with qualified research proposals that may benefit RVCL in some capacity. Whether this be a better fundamental understanding of the disorder, a new treatment modality, or a better way to identify patients…
…the Clayco Foundation understands and generously supports academic research under the category of “RVCL.”
Clinical application is one of the main goals of this entire venture, whether it be treating symptoms, delaying progression, or curing RVCL. Clinical trials are ongoing, with more to soon come online, and we will aim to work with and support those efforts…
…the right trial can change the world.
The Clayco Foundation has lofty goals, as do all world-changing initiatives. This 501c3 organization is set up to accelerate all efforts in 2022, in part beginning with a new online presence and continual updates.
Please follow us on LinkedIn and Facebook to receive regular updates on the research and to support our cause.